Ukko was founded by Anat Binur, Yanay Ofran in 2016.

Who are Ukko's investors?

Ukko's investors include Israel Biotech Fund, Khosla Ventures, Sanara Capital, Western Technology Investment, Fall Line Capital, Leaps by Bayer, PeakBridge VC.

How much funding has Ukko raised?

Ukko has disclosed $47.7M raised across 2 rounds.

Where is Ukko headquartered?

Ukko is headquartered in Mountain View, US.

Ukko

Mountain View, US · Founded 2016 · Delaware corporation · 58 employees on LinkedIn · 7 known investors

Find your way into Ukko

269 people in our graph share verified history with the Ukko team — schools, employers, funds. One of them is your warm intro.

Lisa Cohenunlockedknows Judith Weiss Paltiel · together at The Hebrew University of Jerusalem (overlapped)

×4knows the team · via Columbia University

knows the team · via Ukko

×5knows the team · via The Hebrew University of Jerusalem

knows the team · via Biolojic Design

Ukko develops immuno-therapeutics for life-threatening food allergies using a computational protein design platform. It applies AI and protein micro-engineering to create modified allergens that retrain the immune system to tolerate the allergen without triggering an allergic response.

AI & Machine Learning Biotech Digital Health

Founders & leadership

Ukko was founded in 2016 by Anat Binur and Yanay Ofran.

Anat BinurinCo-founder and CEO2016–2025

Yanay Ofran inCo-Founder and ChairmanYanay Ofran is co-founder and chairman of Ukko, which develops immunotherapeutics for food allergies using computational protein design. He holds a Ph.D. in Molecular Biophysics and Biomedical Informatics from Columbia University and was previously a professor of bioinformatics at Bar-Ilan University.

Judith Weiss Paltiel inPhD, VP DevelopmentJudith Weiss Paltiel is VP of Development at Ukko and holds a PhD. She has 20+ years of experience in pharmaceutical R&D, with expertise in biologic manufacturing scale-up, protein engineering, analytical methods development, and regulatory submissions including INDs and CTAs across global markets.

Board

Scott BradyBoard director

Samir Kaul in 𝕏Board MemberInvestor at Khosla Ventures

Investors · 7

Israel Biotech FundRehovot

Khosla VenturesMenlo Park · $5K – $50M

Sanara CapitalRa'ananavia Assaf Barnea · inferred

Western Technology InvestmentPortola Valley · $250K – $30M

Fall Line CapitalreportedSan Francisco

Leaps by Bayerreported · 2 sourcesLeverkusen

PeakBridge VCreportedUtrecht

Funding

SEC filings, press & company announcements

$47.7M disclosed across 2 rounds · 2017–2021

$40MSeries BJan 2021 · 3 sources
Leaps by Bayer (lead)
Source ↗

▶$7.7MraisedJul 2017 · 5 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Anat BinurExecutive Officer, Director
Yanay OfranDirector
Scott BradyDirector
Samir KaulDirector

Offering amount: $7.7M
Amount sold: $7.7M
First sale: Jul 2017
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Ukko went on to found or lead other companies.

Uri LopatinCEOFounded Assemblybio +1 Yanay OfranDirectorFounded Biolojic Design +1

In the news

Company Raises $40 Million to Develop Peanut Allergy Therapy and Gluten Safe for Celiac and Intolerances - SnackSafely.comsnacksafely.com · Jan 2021

Ukko Raises $40M in Series B Funding - FinSMEsfinsmes.com · Jan 2021

Food allergies: Biotech startup Ukko secures $40M Series Bnuadox.com · Jan 2021

Ukko secures USD 40 million in Series B funding led by Leaps by Bayer to overcome food allergies and sensitivitiesbayer.com · Jan 2021

Ukko raises $40M for AI-enabled food allergy solutions | Food Divefooddive.com · Jan 2021

Frequently asked questions

What does Ukko do?: Ukko develops immuno-therapeutics for life-threatening food allergies using a computational protein design platform. It applies AI and protein micro-engineering to create modified allergens that retrain the immune system to tolerate the allergen without triggering an allergic response.
Who founded Ukko?: Ukko was founded by Anat Binur, Yanay Ofran in 2016.
Who are Ukko's investors?: Ukko's investors include Israel Biotech Fund, Khosla Ventures, Sanara Capital, Western Technology Investment, Fall Line Capital, Leaps by Bayer, PeakBridge VC.
How much funding has Ukko raised?: Ukko has disclosed $47.7M raised across 2 rounds.
Where is Ukko headquartered?: Ukko is headquartered in Mountain View, US.